Natixis’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21.8M | Sell |
156,715
-473,116
| -75% | -$66.3M | 0.08% | 178 |
|
|
2025
Q4 | $77.3M | Sell |
629,831
-46,609
| -7% | -$5.66M | 0.27% | 52 |
|
|
2025
Q3 | $75.1M | Buy |
676,440
+295,687
| +78% | +$33.6M | 0.35% | 46 |
|
|
2025
Q2 | $42.2M | Buy |
380,753
+116,861
| +44% | +$12.4M | 0.19% | 77 |
|
|
2025
Q1 | $29.5M | Sell |
263,892
-6,302
| -2% | -$650K | 0.16% | 100 |
|
|
2024
Q4 | $25M | Sell |
270,194
-131,347
| -33% | -$11.8M | 0.15% | 110 |
|
|
2024
Q3 | $33.7M | Buy |
401,541
+70,769
| +21% | +$5.4M | 0.19% | 91 |
|
|
2024
Q2 | $22.7M | Buy |
330,772
+178,546
| +117% | +$11.9M | 0.13% | 128 |
|
|
2024
Q1 | $11.2M | Buy |
152,226
+43,916
| +41% | +$3.38M | 0.06% | 220 |
|
|
2023
Q4 | $8.77M | Sell |
108,310
-246,955
| -70% | -$19.2M | 0.06% | 233 |
|
|
2023
Q3 | $26.6M | Sell |
355,265
-248,800
| -41% | -$19.1M | 0.2% | 106 |
|
|
2023
Q2 | $46.6M | Sell |
604,065
-66,061
| -10% | -$5.27M | 0.38% | 53 |
|
|
2023
Q1 | $55.6M | Buy |
670,126
+160,471
| +31% | +$13.3M | 0.5% | 40 |
|
|
2022
Q4 | $43.8M | Sell |
509,655
-549,140
| -52% | -$43.5M | 0.25% | 103 |
|
|
2022
Q3 | $65.5M | Buy |
1,058,795
+214,375
| +25% | +$13.5M | 0.31% | 55 |
|
|
2022
Q2 | $52.2M | Sell |
844,420
-1,409,680
| -63% | -$87.3M | 0.19% | 67 |
|
|
2022
Q1 | $134M | Buy |
2,254,100
+1,853,000
| +462% | +$118M | 0.47% | 30 |
|
|
2021
Q4 | $29.1M | Buy |
401,100
+165,655
| +70% | +$11.4M | 0.1% | 179 |
|
|
2021
Q3 | $16.4M | Sell |
235,445
-1,263,396
| -84% | -$88.8M | 0.06% | 267 |
|
|
2021
Q2 | $103M | Buy |
1,498,841
+457,272
| +44% | +$30.5M | 0.45% | 43 |
|
|
2021
Q1 | $67.3M | Sell |
1,041,569
-290,971
| -22% | -$18.8M | 0.22% | 96 |
|
|
2020
Q4 | $77.6M | Buy |
1,332,540
+386,057
| +41% | +$23.3M | 0.28% | 79 |
|
|
2020
Q3 | $59.8M | Buy |
946,483
+637,447
| +206% | +$44.2M | 0.44% | 58 |
|
|
2020
Q2 | $23.8M | Buy |
309,036
+286,749
| +1,287% | +$22M | 0.18% | 106 |
|
|
2020
Q1 | $1.67M | Sell |
22,287
-1,899,295
| -99% | -$131M | 0.01% | 411 |
|
|
2019
Q4 | $125M | Buy |
1,921,582
+1,155,273
| +151% | +$75.2M | 0.77% | 19 |
|
|
2019
Q3 | $48.6M | Buy |
766,309
+399,942
| +109% | +$26.1M | 0.31% | 79 |
|
|
2019
Q2 | $24.8M | Sell |
366,367
-108,459
| -23% | -$7.13M | 0.19% | 110 |
|
|
2019
Q1 | $30.2M | Sell |
474,826
-172,331
| -27% | -$11.5M | 0.19% | 122 |
|
|
2018
Q4 | $40.5M | Sell |
647,157
-2,178,597
| -77% | -$152M | 0.33% | 78 |
|
|
2018
Q3 | $218M | Buy |
2,825,754
+912,219
| +48% | +$68.9M | 1.26% | 10 |
|
|
2018
Q2 | $136M | Buy |
1,913,535
+1,872,389
| +4,551% | +$132M | 0.72% | 28 |
|
|
2018
Q1 | $3.1M | Sell |
41,146
-275,059
| -87% | -$21.9M | 0.02% | 441 |
|
|
2017
Q4 | $22.7M | Sell |
316,205
-2,021,485
| -86% | -$154M | 0.17% | 134 |
|
|
2017
Q3 | $189M | Buy |
2,337,690
+1,598,343
| +216% | +$122M | 1.75% | 6 |
|
|
2017
Q2 | $52.3M | Buy |
739,347
+476,969
| +182% | +$31.7M | 0.59% | 43 |
|
|
2017
Q1 | $17.8M | Buy |
262,378
+161,746
| +161% | +$11.4M | 0.22% | 116 |
|
|
2016
Q4 | $7.21M | Buy |
+100,632
| New | +$7.48M | 0.07% | 220 |
|
|
2016
Q3 | – | Sell |
-18,831
| Closed | -$1.57M | – | 542 |
|
|
2016
Q2 | $1.57M | Sell |
18,831
-412,480
| -96% | -$36.6M | 0.03% | 231 |
|
|
2016
Q1 | $39.6M | Sell |
431,311
-139,010
| -24% | -$12.5M | 0.66% | 39 |
|
|
2015
Q4 | $57.7M | Buy |
570,321
+16,262
| +3% | +$1.69M | 0.96% | 20 |
|
|
2015
Q3 | $54.4M | Buy |
+554,059
| New | +$61.5M | 1.14% | 20 |
|
Other funds holding GILD
VCM
VPM
Natixis's GILD Position: Q1 2026 in Review
Natixis reduced its Gilead Sciences (GILD) stake by 75% in Q1 2026, selling an estimated $66.3M and leaving 156,715 shares worth $21.8M. The position accounts for 0.08% of the portfolio, ranked #178.
Natixis first reported a position in GILD in Q3 2015 and has held it in 42 quarters since. The position peaked at $218M in Q3 2018. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Natixis held 156,715 shares of Gilead Sciences worth $21.8M as of Q1 2026.
- Natixis sold 473,116 Gilead Sciences shares in Q1 2026, an estimated $66.3M.
- Gilead Sciences made up 0.08% of Natixis's portfolio in Q1 2026, its #178 holding.
- Natixis first reported a position in Gilead Sciences in Q3 2015 and has held it in 42 quarters since.
- Natixis's Gilead Sciences position peaked at $218M in Q3 2018.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.